← Back to Screener
MetaVia Inc. Common Stock (MTVA)
Price$1.51
Favorite Metrics
Price vs S&P 500 (26W)-95.74%
Price vs S&P 500 (4W)-10.20%
Market Capitalization$7.13M
All Metrics
Book Value / Share (Quarterly)$2.88
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-7.39
Price vs S&P 500 (YTD)-87.51%
EPS (TTM)$-8.83
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-8.83
EPS (Annual)$-39.13
ROI (Annual)-347.90%
Cash / Share (Quarterly)$6.49
ROA (Last FY)-169.69%
EBITD / Share (TTM)$-4.55
ROE (5Y Avg)-200.75%
Cash Flow / Share (Annual)$-31.48
P/B Ratio1.13x
P/B Ratio (Quarterly)3.60x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-5.38x
ROA (TTM)-105.28%
EPS Incl Extra (Annual)$-39.13
Current Ratio (Annual)1.94x
Quick Ratio (Quarterly)1.72x
3-Month Avg Trading Volume0.23M
52-Week Price Return-82.67%
Revenue / Employee (TTM)$0
52-Week High$19.03
EPS Excl Extra (Annual)$-39.13
CapEx CAGR (5Y)-47.98%
26-Week Price Return-86.99%
Quick Ratio (Annual)1.94x
13-Week Price Return-74.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.74x
Enterprise Value$-7.15
Revenue / Employee (Annual)$0
Cash / Share (Annual)$20.40
3-Month Return Std Dev121.76%
Net Income / Employee (TTM)$-2
ROE (Last FY)-347.90%
Net Interest Coverage (Annual)-1.14x
EPS Basic Excl Extra (Annual)$-39.13
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-8.83
ROI (TTM)-229.48%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-117.77%
Year-to-Date Return-83.37%
5-Day Price Return-6.67%
EPS Normalized (Annual)$-39.13
ROA (5Y Avg)-125.52%
Month-to-Date Return16.67%
EBITD / Share (Annual)$-40.40
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-200.75%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-8.83
P/B Ratio (Annual)2.31x
Book Value / Share (Annual)$10.10
Price vs S&P 500 (13W)-77.03%
Beta0.49x
Revenue / Share (TTM)$0.00
ROE (TTM)-229.48%
52-Week Low$1.17
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MTVAMetaVia Inc. Common Stock | — | — | — | — | $1.51 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
MetaVia Inc is a clinical-stage biotechnology company developing therapeutics for cardiometabolic diseases, with focus areas in metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The company's pipeline includes DA-1241, a GPR119 agonist targeting MASH and Type 2 Diabetes, and DA-1726, a GLP-1/glucagon receptor dual agonist designed for once-weekly administration in obesity treatment.